Cilostazol Determination by the Enhancement of the Green Emission of Tb3+ Optical Sensor

Hashiguchi M, Ohna K, Nakasawa R, Kishino S, Mochizuki M, Shiga T (2004) Comparison of CIL and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther 18:211–217

Sweet man SC (ed) (2002) In: Martinadale: the complete drug reference, 33 rd edn. Pharmaceutical Press, USA. vol I, pp 258–860

Kishida M, Watanabe K, Tsuruoka T (2001) Effects of cilostazal in patients with bradycardiac arterial fibrillation. J Cardiol 37:27–33

Madias JE (2003) CIL: an “intermittent claudicatio” remedy for management of third degree AV block. Chest 123(4):979–982

Tata PNV, Fu CJ, Browder NJ, Chow PC, Bramer SL (1998) The quantitative determination of CIL and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography. J Pharm Biomed Anal 18(3):441–451

Fu CJ, Tata PNV, Okada K, Akiyama H, Bramer SL (1999) Effect of renal impairment on the pharmacokinetics of CIL and its metabolites. J Chromatogr B Biomed Appl 728:251–262

Tata PNV, Fu CJ, Bramer SL (2001) Determination of CIL and its metabolites in human urine by high performance liquid chromatography. J Pharm Biomed Anal 24:381–389

Bramer SL, Tata PNV, Vengurlekar SS, Brisson JH (2001) Method for the quantitative analysis of CIL and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal 26:637–650

Yeon KJ, Park YJ, Park KM, Ban E, Kim YB, Kim CK (2005) Validated stability-indicating methods for determination of CIL in the presence of its degradation products according to the ICH guidelines. J Liq Chromatogr Relat Technol 28:109–120

Fayed AS, Shehata MA, Ashour A, Hassan NY, Weshahy SA (2007) Validated stability-indicating methods for determination of CIL in the presence of its degradation products according to the ICH guidelines. J Pharm Biomed Anal 45:407–416

Kanthi Kiran VS Varanasi, Sridhar V, Suresh Potharaju, Shraddha R, Sivakumar SPN, Kanaga Sabapathi S, Satheeshmanikandan TRS, Swaroop Kumar VVS (2008) Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. J Chromatogr B 865(1–2):91–98

Al-Arfaj NA (2004) Flow-injection chemiluminescent determination of metoclopramide hydrochloride in pharmaceutical formulations and biological fluids using the [Ru(dipy)2+]–permanganate system. Talanta 62:255–263

Attia MS (2009) Spectrofluorimetric quantification of bromazepam using a highly selective optical probe based on Eu3 + bromazepam complex in pharmaceutical and serum samples. Spectrochim Acta Part A 74:972–976

Attia MS (2010) Spectrofluorimetric assessment of Ramipril using optical sensor Samarium ion–doxycycline complex doped in sol–gel matrix. J Pharm Biomed Anal 51:7–11

Attia MS, Othman AM, Aboaly MM, Abdel-Mottaleb MSA (2010) Novel spectrofluorimetric method for measuring the activity of the enzyme r-L-Fucosidase using the nano composite optical sensor Samarium(III)-Doxycycline complex doped in Sol-Gel matrix. Anal Chem 82(14):6230–6236

International Conference on Hormonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1). Current Step 4 version Parent Guideline dated 27 October 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005)

(1999) British pharmacopoeia, vol. II, Her majesty’s stationary office. London, p. 2705